Screening for Diabetes Mellitus-the World Health Organization Perspective

Prevention of Type 2 Diabetes

Volumn , Issue , 2005, Pages 105-123

  Roglic, Gojka ^a   Williams, Rhys ^b   Colagiuri, Stephen ^c  

^a Diabetes Program   (Switzerland)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Dyslipidaemia; Hypertension; Impaired fasting glucose (IFG); Impaired glucose tolerance (IGT); Oral glucose tolerance test (OGTT); Randomized controlled trials (RCTs); Type 2 diabetes

Indexed keywords

EID: 84889627442     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470857358.ch7     Document Type: Chapter

References (60)

1. Wild S, Roglic G, Sicree R, Green A and King H. Global burden of diabetes mellitus in the year 2000. Global Burden of Disease. 2003. Geneva: WHO.
2. King H and Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993; 16: 157-177.
3. Diabetes Atlas, 2nd edn. 2003. Brussels: International Diabetes Federation.
4. Rosenbloom AL et al. Emerging epidemic of Type 2 diabetes in youth. Diabetes Care 1999; 22: 345-354.
5. Dabelea D et al. Increasing prevalence of Type 2 diabetes in American Indian children. Diabetologia 1998; 41: 904-910.
6. Kitagawa T et al. Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correleates with an increased intake of animal protein and fat. Clin Paediatr 1998; 37: 111-115.
7. Morrish NJ,Wang SL, Stevens LK, Fuller JH and Keen H. WHO Multinational Study Group. Mortality and causes of death in theWHOmultinational study of vascular disease in diabetes. Diabetologia 2001; 44 (Suppl. 2): S14-S21.
8. Bell DS. Stroke in the diabetic patient. Diabetes Care 1994; 17: 213-219.
9. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002; 25: S85-S89.
10. Siitonen OI, Niskanen LK, Laakso M, Siitonen JT and Pyörälä K. Lower-extremity amputations in diabetic and nondiabetic patients. Diabetes Care 1993; 16: 16.
11. Anonymous. From the Centres for Disease Control and Prevention. Blindness caused by diabetes. JAMA 1996; 276: 1865-1866.
12. Kuzuya T, Akanuma Y, Akazawa Y and Uehata T. Prevalence of chronic complications in Japanese diabetic patients. Diabetes Res Clin Practice 1994; 24 (Suppl.): S159-S164.
13. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998; 21: 296-309.
14. International Diabetes Federation and World Health Organization. The Economics of Diabetes and Diabetes Care 1996. Brussels: International Diabetes Federation.
15. Harris MI, Klein R, Welborn TA and Knuiman MW. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15(7): 815-825.
16. Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES and Badran A et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med 1996; 13: 337-340.
17. UK Prospective Diabetes Study (UKPDS) Group. The UK Prospective Diabetes Study 30. Diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998; 116: 670-677.
18. King H, Aubert RE and Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care 1998; 21: 1414-1431.
19. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S and Motoyoshi S. Intensive insulin therapy prevents the progession of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomised prospective 6-year study. Diabetes Res Clin Practice 1995; 28: 103-117.
20. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
21. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in Type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
22. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG and Thorgeirsson G et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-620.
23. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard WJ and Davis BR et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998; 98: 2513-2519.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002; 360: 7-22.
25. Huang ES, Meigs JB and Singer DE. The effect of interventions to prevent cardiovascular disease in patients with Type 2 diabetes mellitus. Am J Med 2001; 111: 633-642.
26. Screening for Type 2 Diabetes Mellitus. Report of a World Health Organization and International Diabetes Federation Meeting. WHO/NMH/MNC/03.1. 2003. Geneva: World Health Organization.
27. International Diabetes Federation. International Diabetes Federation IGT/IFG Consensus Statement. Report of an Expert ConsensusWorkshop. 2001. Brussels: International Diabetes Federation pp. 1-34.
28. Hamman RF. Prevention of Type 2 diabetes. In The Evidence Base for Diabetes Care, Williams R, Herman W, Kinmonth AL and Wareham NJ (eds). 2002. Chichester: Wiley, pp. 75-176.
29. The Cost-Effectiveness of DPP Interventions to Delay or Prevent Type 2 Diabetes. American Diabetes Association Annual Meeting 2002. San Francisco: American Diabetes Association.
30. Griffin S, Little PS, Hales CN, Kinmonth AL and Wareham NJ. Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice. Diabetes/Metab Res Rev 2000; 16: 164-171.
31. O'Connor PJ, RushWA, Cherney LM and Pronk NP. Screening for diabetes mellitus in highrisk patients: cost, yield and acceptability. Effective Clin Pract 2001; 4: 271-277.
32. Sasco AJ. Validity of case-control studies and randomized controlled trials of screening. Int J Epidemiol 1991; 20: 1143-1144.
33. Sasco AJ. Lead time and length bias in case-control studies for the evaluation of screening. J Clin Epidemiol 1988; 41: 103-104.
34. Sasco AJ, Day NE and Walter SD. Case-control studies for the evaluation of screening. J Chron Dis 1986; 39: 399-405.
35. Bossuyt PM, Reitsma JB, Burns DE, Gastonis CA, Glasziou PP and Irwig LM et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003; 326: 41-44.
36. Straus SE. Reporting diagnostic tests. BMJ 2003; 326: 3-4.
37. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for Type 2 diabetes. JAMA 1998; 280: 1757.
38. Kuo HS, Chang HJ, Chou P, Teng L and Chen THH. A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 1999; 28: 233-240.
39. Chang H-J, Kuo H-S, Tung T-H, Chou P and Chen TH-H. Evaluation of a population-based screening for Type 2 diabetes: a community-based screening project in Puli, Taiwan. Prevent Med 2000; 31: 396-402.
40. Stewart-Brown S and Farmer A. Screening could seriously damage your health. BMJ 1997; 314: 533-534.
41. Adriaanse MC, Snoek FJ, Dekker JM, van der Ploeg HM and Heine RJ. Screening for Type 2 diabetes: an exploration of subjects' perceptions regarding diagnosis and procedure. Diabet Med 2002; 19: 406-411.
42. Levitt NS, Katzenellenbogen JM, Bradshaw D, Hoffman MN and Bonnici F. The prevalence and identification of risk factors for NIDDM in urban Africans in Cape Town, South Africa. Diabetes Care 1993; 16: 601-607.
43. Mooy JM, Grootenhuis PA, De Vries H, Valkenburg HA, Bouter LM and Kostense PJ et al. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population-The Hoorn Study. Diabetes Care 1995; 18: 1270-1273.
44. Park Y, Lee H, Koh, C-S, Min H and Yoo K et al. Prevalence of diabetes and IGT in Yonchon County, South Korea. Diabetes Care 1995; 18: 545-548.
45. Elbagir MN, Eltom MA, Elmahadi EMA, Kadam IMS and Berne C. A population-based study of the prevalence of diabetes and impaired glucose tolerance in adults in Northern Sudan. Diabetes Care 1996; 19: 1126-1128.
46. Oliveira JEP, Milech A and Franco LJ. The Cooperative Group for the Study of Diabetes Prevalence in Rio de Janeiro. The prevalence of diabetes in Rio de Janeiro, Brazil. Diabet Med 1996; 19: 663-666.
47. Mbanya JCN, Ngogang J, Salah JN, Minkoulou E and Balkau B. Prevalence of NIDDM and impaired glucose tolerance in a rural and an urban population in Cameroon. Diabet Med 1997; 40: 824-829.
48. Ajlouni K, Jaddou H and Batieha A. Diabetes and impaired glucose tolerance in Jordan: prevalence and associated risk factors. J Intern Med 2001; 244: 317-323.
49. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE and Little RR et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-524.
50. Jimenez JTPM, Canẽte F, Barriocanal LA, Medina U, Figueredo R and Martinez S et al. Prevalence of diabetes mellitus and associated cardiovascular risk factors in an adult urban population in Paraguay. Diabet Med 1998; 15: 334-338.
51. Castell C, Tresserras R, Serra J, Goday A, Lloveras G and Salleras L. Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study. Diabetes Res Clin Pract 1999; 43: 33-40.
52. Shera AS, Rafique G, Ahmend KI, Baqai S, Khan IA and King H. Pakistan National Diabetes Survey. Prevalence of glucose intolerance and associated factors in North West Frontier Province (NWFP) of Pakistan. J Pakistan Med Assoc 1999; 49: 206-211.
53. Tan C-E, Emmanuel SC, Tan B-Yand Jacob E. Prevalence of diabetes and ethnic differences in cardiovascular risk factors. The 1992 Singapore National Health Survey. Diabetes Care 1999; 22: 241-247.
54. Sekikawa A, Eguchi H, Tominaga M, Igarashi K, Abe T and Manaka H et al. Prevalence of Type 2 diabetes mellitus and impaired glucose tolerance in a rural area of Japan. The Funagata diabetes study. J Diabetes Complications 2000; 14: 78-83.
55. Ramachandran A, Snehalatha C, Kapur A, Vijay V and Mohan V and Das AK et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001; 44: 1094-1101.
56. Amoah AG, Owusu SK and Adjei S. Diabetes in Ghana: a community based prevalence study in Greater Accra. Diabetes Res Clin Pract 2002; 56: 197-205.
57. Dunstan DW, Zimmet P, Welborn TA, De Courten MP, Cameron AJ and Sicree RA. The rising prevalence of diabetes and impaired glucose tolerance. The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834.
58. Satman I, Aengû l A, Salman S, Tûtûncû Y, Sargin M and Dinccag N et al. Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish Diabetes Epidemiology Study. Diabetes Care 2002; 25: 1551-1556.
59. Suvd J, Gerel B, Otgooloi H, Purevsuren D, Zolzaya H and Roglic G et al. Glucose intolerance and associated factors in Mongolia: results of a national survey. Diabet Med 2002; 19: 502-508.
60. Colagiuri S, Colagiuri R, Na'ati S, Muimuiheata S, Hussain Z and Palu T. The prevalence of diabetes in the Kingdom of Tonga. Diabetes Care 2002; 25: 1378-1383.